Theriva Biologics, Inc.
Company Information
Industry
Pharmaceutical Preparations
SIC Code
2834
Entity Type
operating
SEC Category
Non-accelerated filerSmaller reporting company
State of Incorporation
NV
Business Address
9605 MEDICAL CENTER DRIVE, ROCKVILLE, MD, 20850
Mailing Address
9605 MEDICAL CENTER DRIVE, ROCKVILLE, MD, 20850
Phone
(734) 332-7800
Fiscal Year End
1231
EIN
133808303
Financial Overview
FY2025
$22.86M
Total Liabilities
Recent SEC Filings
| Form Type | Date Filed | Document |
|---|---|---|
| 8-K Current report of material events | March 23, 2026 | View on SEC |
| DEF 14A Definitive proxy statement | March 16, 2026 | View on SEC |
| 8-K Current report of material events | March 12, 2026 | View on SEC |
| 10-K Annual financial report | March 12, 2026 | View on SEC |
| 8-K Current report of material events | February 18, 2026 | View on SEC |
| 8-K Current report of material events | February 12, 2026 | View on SEC |
| 8-K Current report of material events | January 12, 2026 | View on SEC |
| 4 Insider stock transaction report | January 6, 2026 | View on SEC |
| 4 Insider stock transaction report | January 6, 2026 | View on SEC |
| 4 Insider stock transaction report | January 6, 2026 | View on SEC |
Annual Reports
10-K
March 12, 2026
- Theriva Biologics develops novel treatments for infectious diseases and neurological disorders, advancing drug candidates through clinical trials.
- The company aims to bring new therapies to market by continuing clinical development of its lead drug candidates and generating compelling data.
Material Events
8-K
Financial Distress
March 12, 2026
High Impact
- Promising clinical and regulatory progress for lead drug candidate VCN-01.
- Strategic SYN-020 licensing deal provides non-dilutive funding and sharpens focus on VCN-01.
Related Companies
Companies in the same industry (SIC: 2834)
Investor Resources
Learn more about SEC filings and how to research public companies.
What is the SEC?
A plain English guide to the Securities and Exchange Commission
Understanding SEC Filings & CIK
How to navigate SEC filings and Central Index Keys
10-K Annual Reports Explained
Everything you need to know about annual reports
S-1 & F-1 IPO Filings
Understanding IPO registration statements
SEC EDGAR Database Guide
How to use the SEC's free filing database
Important Disclaimer
This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.